Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation
Article first published online: 17 SEP 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 29, Issue 1, pages 104–114, January 2009
How to Cite
AGRAWAL, A., HOUGHTON, L. A., MORRIS, J., REILLY, B., GUYONNET, D., GOUPIL FEUILLERAT, N., SCHLUMBERGER, A., JAKOB, S. and WHORWELL, P. J. (2009), Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics, 29: 104–114. doi: 10.1111/j.1365-2036.2008.03853.x
- Issue published online: 16 DEC 2008
- Article first published online: 17 SEP 2008
- Publication data Submitted 23 July 2008 First decision 25 July 2008 Resubmitted 8 August 2008; 8 September 2008 Accepted 12 September 2008 Epub Accepted Article 17 September 2008
Background A sensation of abdominal swelling (bloating) and actual increase in girth (distension) are troublesome features of irritable bowel syndrome (IBS), which is more common in patients with constipation, especially those with delayed transit.
Aim To establish whether a fermented dairy product containing Bifidobacterium lactis DN-173 010 reduces distension in association with acceleration of gastrointestinal transit and improvement of symptoms in IBS with constipation.
Methods A single centre, randomized, double-blind, controlled, parallel group study in which patients consumed the test product or control product for 4 weeks. Distension, orocaecal and colonic transit and IBS symptoms were assessed on an intention-to-treat population of 34 patients.
Results Compared with control product, the test product resulted in a significant reduction in the percentage change in maximal distension [median difference – 39%, 95% CI (−78, −5); P = 0.02] and a trend towards reduced mean distension during the day [−1.52 cm (−3.33, 0.39); P = 0.096]. An acceleration of orocaecal [−1.2 h (−2.3,0); P = 0.049] as well as colonic [−12.2 h (−22.8, −1.6); P = 0.026] transit was observed and overall symptom severity [−0.5 (−1.0, −0.05); P = 0.032] also improved.
Conclusions This probiotic resulted in improvements in objectively measured abdominal girth and gastrointestinal transit, as well as reduced symptomatology. These data support the concept that accelerating transit is a useful strategy for treating distension.